TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31227397
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TXA injections)
Study: 27881670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with three daily isoenergetic meals
Study: 23624489
Drug: CB1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB1 receptor binding in SCZ patients (SCZ-T and SCZ-F)
Study: 23624489
Drug: CB1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB1 receptor binding in SCZ-F patients
Study: 19801100
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg intraoperative dexamethasone
Study: 19801100
Drug: 0.7 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg intraoperative dexamethasone
Study: 12837712
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication intervention (paroxetine switched to bupropion if lack of response) (n = 88)
Study: 12837712
Drug: Psychotherapy intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychotherapy intervention (8 weeks of manual-guided cognitive behavior therapy) (n = 90)
Study: 10333940
Drug: Diagnosis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis of diabetes based on 2-h glucose load after a 75-g glucose load.
Study: 341940
Drug: Mianserin hydrochloride
Normalized name: Mianserin hydrochloride
DrugBank: Mianserin (DB06148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin hydrochloride 20 mg
Study: 341940
Drug: Mianserin 20
Normalized name: mianserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 20 mg three times daily
Study: 341940
Drug: Desmethylimipramine 25
Normalized name: Desmethylimipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desmethylimipramine 25 mg three times daily
Study: 29175121
Drug: Elevated unmethylated
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated unmethylated insulin DNA
Study: 29175121
Drug: Elevated methylated
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated methylated insulin DNA
Study: 27416887
Drug: Fludrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (50 μg oral dose)
Study: 12271805
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy for the prevention of psychosis
Study: 31314108
Drug: darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 800/100 mg monotherapy
Study: 28625256
Drug: Norepinephrine (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (> 1 μg/min)
Study: 25736441
Drug: Dose change-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose change-based method for calculating individual patient time in therapeutic range (iTTR)
Study: 19327603
Drug: Urapidil (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (12.5 mg, ic)
Study: 10611189
Drug: Melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 6 mg orally every day at 1700 h for 1 month
Study: 9189814
Drug: Elastase (10800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastase (10800 EL. U. P.O. per day) with an antiplatelet drug
Study: 9189814
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only antiplatelet drug)
Study: 9189814
Drug: Elastase (10800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastase (10800 EL. U. P.O. per day) with an antiplatelet drug (when autogenous saphenous veins were used)
Study: 9189814
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only antiplatelet drug, when autogenous saphenous veins were used)
Study: 3887547
Drug: Antacid (Novaluzid;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Novaluzid; 10 ml seven times daily, with a neutralizing capacity of 600 mmol H+)
Study: 29651052
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine based multiple injections (MDI) therapy
Study: 22732135
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of mood, stress, and daily activities for 2 to 4 weeks.
Study: 22732135
Drug: Attention comparison
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention comparison group (only daily activities monitored) for 2 to 4 weeks.
Study: 20032123
Drug: Concomitant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiotherapy (CT/RT) alone (arm A: two cycles of cisplatin 20 mg/m(2), days 1-4, plus 5‐fluorouracil 800 mg/m(2)/day 96 h continuous infusion during weeks 1 and 6 of radiotherapy)
Study: 20032123
Drug: Induction docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction docetaxel, cisplatin and 5‐fluorouracil (TPF) followed by concomitant chemoradiotherapy (arm B: three cycles of TPF: docetaxel 75 mg/m(2) and cisplatin 80 mg/m(2), day 1, and 5‐fluorouracil 800 mg/m(2)/day 96 h continuous infusion, every 3 weeks)
Study: 10834024
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamins (30,000 IU vitamin A, 1 g vitamin C, 70 mg vitamin E, 2 g calcium)
Study: 10834024
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamins (after 6 months discontinuation)
Study: 10834024
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after 6 months discontinuation)
Study: 8861437
Drug: Gelseal Vascutek
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelseal Vascutek graft immersed for 15 min in a solution containing 1 mg/ml rifampicin (group A)
Study: 6147067
Drug: Basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal therapy (B) with monthly appointments
Study: 27486681
Drug: Tübingen exercise
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tübingen exercise therapy approach (THüKo)
Study: 18840133
Drug: Immunohistochemical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical analysis using Ber‐EP4 antibody
Study: 18840133
Drug: Immunohistochemical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical analysis using AE1/AE3 antibody
Study: 18840133
Drug: Immunohistochemical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical analysis using CAM 5.2 antibody
Study: 16504324
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum MF1298
Study: 16504324
Drug: L. pentosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. pentosus DC13
Study: 16504324
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum MF1298 (as sausage)
Study: 16504324
Drug: L. pentosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. pentosus DC13 (as sausage)
Study: 11062570
Drug: Topical lignocaine‐prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lignocaine‐prilocaine anaesthetic cream
Study: 9258888
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg of lactated ringer intravenously as prehydration
Study: 2685045
Drug: Tailored psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored psychological treatment of insomnia
Study: 2685045
Drug: Untailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untailored treatment (stimulus control therapy)
Study: 25572279
Drug: Calmare® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calmare® treatment (up to 10 sessions)
Study: 25572279
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (non-therapeutic threshold)
Study: 25572279
Drug: Calmare® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calmare® treatment
Study: 21490695
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g) and E (800 IU)
Study: 16785153
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (GnRH‐ant)
Study: 15169798
Drug: Three rF‐PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three rF‐PSA vaccines followed by one vaccinia‐PSA (rV‐PSA) vaccine
Study: 15169798
Drug: One rV‐PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: One rV‐PSA vaccine followed by three rF‐PSA vaccines
Study: 15169798
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with poxviruses expressing PSA
Study: 9233107
Drug: Timed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-dose
Study: 8425810
Drug: Topical paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paromomycin treatment
Study: 30356343
Drug: Paracervical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical injection of 0.25% bupivacaine with epinephrine
Study: 15067655
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL normal saline)
Study: 21951314
Drug: SB‐705498 (TRPV1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB‐705498 (TRPV1 blocker) administered via nasal lavage 2 minutes before each allergen challenge.
Study: 16192763
Drug: 22.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg/kg acetaminophen
Study: 16192763
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg acetaminophen
Study: 16192763
Drug: Acetaminophen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (all doses)
Study: 9288701
Drug: Estraderm MX
Normalized name: Estraderm MX
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estraderm MX 50 (0.05 mg estradiol per day)
Study: 7506145
Drug: Nimesulide (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100mg twice daily)
Study: 7506163
Drug: Naproxen (250mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250mg twice daily)
Study: 3828183
Drug: 3% 2‐chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% 2‐chloroprocaine 23 ml administered in head-up position
Study: 3828183
Drug: 3% 2‐chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% 2‐chloroprocaine 23 ml administered in supine position
Study: 29885026
Drug: Telephone-delivered exercise
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered exercise therapy
Study: 26280247
Drug: Polypill strategy
Normalized name: POLYPILUS FRONDOSUS WHOLE
DrugBank: Grifola frondosa whole (DB19262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill strategy (containing a statin, antiplatelet agent, and two blood-pressure-lowering medications)
Study: 21823422
Drug: Tangzu Yuyang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangzu Yuyang Ointment (TYO) plus Standard Wound Therapy (SWT)
Study: 21823422
Drug: Standard Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Wound Therapy (SWT)
Study: 17368881
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) supplementation (2.2 g daily for 8 weeks)
Study: 14687104
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug administration system
Study: 9745973
Drug: Midodrine hydrochloride,
Normalized name: Midodrine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine hydrochloride, dosage and duration not specified
Study: 7818196
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g) combined with nalbuphine hydrochloride (10 mg)
Study: 7818196
Drug: Nalbuphine hydrochloride
Normalized name: Nalbuphine Hydrochloride
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine hydrochloride (20 mg)
Study: 31980022
Drug: Flaxseed powder
Normalized name: Flaxseed Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed powder (30 g/day) plus lifestyle modification
Study: 30895611
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (400 mg, three times per day for 7 days)
Study: 30895611
Drug: Combined vaginal
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined vaginal tablet (nystatin 100,000 U, diiodohydroxyquin 100 mg, benzalkonium chloride 7 mg, once daily for 7 days)
Study: 30895611
Drug: Combined vaginal
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined vaginal tablet
Study: 23128968
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice a day plus aspirin 100 mg a day
Study: 23128968
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin 100 mg a day
Study: 19388074
Drug: Targeted care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted care bundle consisting of medication counseling/reconciliation by a clinical pharmacist, condition specific education/enhanced discharge planning by a care coordinator, and phone follow-up.
Study: 308770
Drug: Sensory-stimulating treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory-stimulating treatment for eight weeks
Study: 28809610
Drug: Cabazitaxel 20
Normalized name: cabazitaxel 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel 20 mg/m2 (C20)
Study: 28809610
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m2 (C25)
Study: 15625211
Drug: Clozapine +
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine + Risperidone (up to 6 mg/day)
Study: 12169075
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (200 mg)
Study: 8723585
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (150 IU/kg subcutaneously on alternate days; six doses)
Study: 2054690
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg intramuscularly
Study: 2054690
Drug: Diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15 mg intramuscularly
Study: 31825024
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education sessions delivered by trained schoolteachers
Study: 31825024
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no extra oral health education)
Study: 28120629
Drug: ropinirole PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropinirole PR 8 mg/day
Study: 28120629
Drug: ropinirole PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropinirole PR 12 mg/day
Study: 25827078
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture only without subcuticular skin suture (case group, n=68)
Study: 25827078
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture and subcuticular skin suture (control group, n=70)
Study: 23873992
Drug: Biological factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological factors (early neonatal mortality)
Study: 19249945
Drug: Ropinirole (0.25-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.25-6 mg)
Study: 16752943
Drug: Hexylaminolevulinate 4
Normalized name: aminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexylaminolevulinate 4 mmol/L
Study: 16752943
Drug: Hexylaminolevulinate 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexylaminolevulinate 8 mmol/L
Study: 16752943
Drug: Hexylaminolevulinate 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexylaminolevulinate 16 mmol/L
Study: 14737056
Drug: Humalog (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humalog (insulin lispro)
Study: 11719362
Drug: Orbofiban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbofiban (oral GPIIb/IIIa antagonist)
Study: 15305178
Drug: linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: linoleic acid (L fat)
Study: 10834505
Drug: Preoperative hypervolaemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative hypervolaemic haemodilution using hydroxyethyl starch, followed by intraoperative crystalloid infusion
Study: 2005168
Drug: Local injections
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injections of corticosteroid and local anaesthesia
Study: 2005168
Drug: Manipulation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation and injection
Study: 3927764
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate 1.8 g in 10 ml of saline intravenously
Study: 3927764
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection of 10 ml of saline intravenously
Study: 30203763
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine Kouchuang Xiaotong powder
Study: 30203763
Drug: General routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: General routine treatment
Study: 24092662
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 75/25 (LM75/25)
Study: 18044772
Drug: Miconazole 50-mg
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole 50-mg mucoadhesive buccal tablet (MBT)
Study: 18044772
Drug: Miconazole 500-mg
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole 500-mg oral gel (MOG)
Study: 12635389
Drug: Midazolam 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.015 mg/kg i.v.
Study: 1391062
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon gamma (0.1 mg, subcutaneously 3 times a week for 6 weeks)
Study: 3977198
Drug: Intervention: Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Treatment algorithm to increase patient involvement in care during a 20-minute session before a scheduled visit.
Study: 3977198
Drug: Intervention: Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Treatment algorithm to increase patient involvement in care.
Study: 27965848
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding plus pre-treatment gastrostomy tube
Study: 27965848
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding plus as-needed nasogastric tube feeding
Study: 25217473
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 2 mg/kg
Study: 25217473
Drug: Intranasal alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal alfentanil 10 µg/kg
Study: 25217473
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 1 ml
Study: 23236769
Drug: Hormone
Normalized name: Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone
Study: 23236769
Drug: XAP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAP and Hormone
Study: 23236769
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three groups (XAP, Hormone, XAP and Hormone)
Study: 23236769
Drug: XAP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAP and Hormone vs Hormone
Study: 20078514
Drug: Periprostatic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic injection of levobupivacaine
Study: 20078514
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository and levobupivacaine
Study: 13130389
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg)
Study: 9925116
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion (11.97 kJ/min, or 2.86 kcal/min)
Study: 9925116
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (11.97 kJ/min)
Study: 9925116
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion (saline)
Study: 2297824
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine infusion
Study: 2297824
Drug: Aminophylline after
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline after intracoronary adenosine infusion
Study: 7358209
Drug: Hydroderm ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroderm ointment base (1% hydrocortisone)
Study: 7358209
Drug: Established hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Established hydrocortisone ointment formulation